Question to the Home Office:

To ask the Secretary of State for the Home Department, with reference to her Department's correspondence entitled ACMD 3-year work programme 2025 to 2028: commissioning letter, published on 2 June 2025, if she will consult families of people reliant on medical cannabis to treat drug-resistant epilepsy as part of the review of Cannabis-Based Products for Medicinal Use.

The Government commissioned the Advisory Council on the Misuse of Drugs (‘ACMD’) to review the current evidence on cannabis-based products for medicinal (‘CBPMs’) on 2 June 2025. The commission invited the ACMD to consider whether the legislation has had the desired impact and any unintended consequences, including on clinical trials.

The Government recognises the importance of this matter to families who are affected by conditions like drug-resistant epilepsy, and this is why we have asked the ACMD to prioritise this work. The ACMD is an independent scientific advisory body and determines its own procedures. The Government has confidence in its ability to consider the full breadth of the evidence. The Government will consider the ACMD’s advice carefully before taking any action.